• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DURVALUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • DURVALUMAB chembl:CHEMBL3301587 ApprovedAntineoplastic

    Alternate Names:

    DURVALUMAB
    MEDI-4736
    IMFINZI
    MEDI4736
    drugbank:11714
    chemidplus:1428935-60-7
    chembl:CHEMBL3301587

    Drug Info:

    (4 More Sources)

    Publications:

    Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Aguiar et al., 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data., Immunotherapy
    Faiena I et al., 2018, Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma., Drug Des Devel Ther
    Lee HT et al., 2017, Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab., Sci Rep
    Bellmunt J et al., 2017, A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now., Cancer Treat Rev
    Castro et al., 2015, Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations., J Immunother Cancer
    Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science
  • DURVALUMAB   MSH2

    Interaction Score: 20.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26674132


    Sources:
    CIViC

  • DURVALUMAB   MSH6

    Interaction Score: 10.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26674132


    Sources:
    CIViC

  • DURVALUMAB   CD274

    Interaction Score: 7.73

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Programmed cell death 1 ligand 1 inhibitor
    Direct Interaction yes

    PMIDs:
    28472902 29416316 28717238 28214651


    Sources:
    ChemblInteractions CIViC PharmGKB TTD FDA

  • DURVALUMAB   PBRM1

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29301960


    Sources:
    CIViC

  • DURVALUMAB   ALK

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694


    Sources:
    JAX-CKB

  • DURVALUMAB   EGFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 31086949


    Sources:
    JAX-CKB CIViC

  • JAX-CKB: Durvalumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.

  • CIViC: DURVALUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Castro et al., 2015, Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations., J Immunother Cancer
    Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science

  • TTD: MEDI4736

    • Version: 2020.06.01

    Alternate Names:
    D04RRZ TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Durvalumab

    • Version: 2020.06.01

    Alternate Names:
    D0LS9E TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3301587

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Durvalumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3301587

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: durvalumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21